In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Inverness Medical buys Cholestech for $299mm in stock

02 Jul 2007

Executive Summary

Inverness Medical Innovations will acquire fellow point-of-care diagnostics company Cholestech by providing shareholders with 0.44 shares of Inverness common stock for each Cholestech share they own or about $19.17 per share (a 12% premium), for a total of $299mm.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Glucose Testing
    • Therapeutic Drug Monitoring
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By